SCHEMBL21296954

SCHEMBL21296954

COc1ccc(-c2cccc(Oc3[nH]nnc3C(=O)O)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAG1 P54619 1/20 0.50
PRKAA1 Q13131 1/20 0.50
PRKAB1 Q9Y478 1/20 0.50
FFAR1 O14842 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
PIN1 Q13526 1/20 0.46
ALPL P05186 1/20 0.45
CA9 Q16790 1/20 0.45
HAO1 Q9UJM8 2/20 0.45
XDH P47989 1/20 0.44
ABL1 P00519 1/20 0.43
ABCB1 P08183 1/20 0.43
BCR P11274 1/20 0.43
DHODH Q02127 1/20 0.43
MCL1 Q07820 1/20 0.43
STIM1 Q13586 1/20 0.43
ORAI1 Q96D31 1/20 0.43
DYRK1A Q13627 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799086 1.00 PRKAG1 (0.50) PRKAG1PRKAA1PRKAB1FFAR1FFAR4
SCHEMBL21296929 0.95 PIN1 (0.49) PRKAG1PRKAA1PRKAB1FFAR1FFAR4
SCHEMBL29799092 0.92 PIN1 (0.47) PRKAG1PRKAA1PRKAB1FFAR1FFAR4
SCHEMBL21296926 0.92 PIN1 (0.47) PRKAG1PRKAA1PRKAB1FFAR1FFAR4
SCHEMBL29799085 0.90 HAO1 (0.44) FFAR1FFAR4PIN1HAO1DHODH
SCHEMBL21296859 0.90 HAO1 (0.44) FFAR1FFAR4PIN1HAO1DHODH
SCHEMBL21296953 0.89 FFAR4 (0.47) FFAR4PIN1ALPLHAO1XDH
SCHEMBL29799187 0.89 FFAR4 (0.47) FFAR4PIN1ALPLHAO1XDH
SCHEMBL21296847 0.89 PRKAG1 (0.51) PRKAG1PRKAA1PRKAB1ALPLCA9
SCHEMBL21296979 0.87 HAO1 (0.47) FFAR1FFAR4ALPLHAO1XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX PRKAG1 2580/4885PRKAA1 2860/4885PRKAB1 2716/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX PRKAG1 2580/4885PRKAA1 2860/4885PRKAB1 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.